https://scholars.lib.ntu.edu.tw/handle/123456789/634648
Title: | Afatinib for the treatment of non-small-cell lung cancer with unusual EGFR mutations: a plain language summary | Authors: | CHIH-HSIN YANG | Keywords: | EGFR mutation; afatinib; lay summary; non-small-cell lung cancer; plain language summary | Issue Date: | Feb-2023 | Journal Volume: | 19 | Journal Issue: | 4 | Source: | Future oncology (London, England) | Abstract: | EGFR is a protein on cells that helps control their growth and division. Mutations in the gene for EGFR can cause cancer, including some cases of non-small-cell lung cancer (NSCLC). Afatinib is a medicine that blocks mutated EGFR and helps kill cancer cells. Many different types of EGFR mutation have been identified in people with NSCLC. Over three quarters of cases are caused by two types of EGFR mutation, known as common EGFR mutations, but some cases are caused by unusual/uncommon EGFR mutations. People with NSCLC who have these unusual/ uncommon EGFR mutations are often excluded from clinical trials. Consequently, researchers don't really know how well medicines like afatinib work in these people. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/634648 | ISSN: | 14796694 | DOI: | 10.2217/fon-2022-0842 |
Appears in Collections: | 醫學院附設癌醫中心醫院(臺大癌醫) |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.